Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TransCode Therapeutics ( (RNAZ) ) has shared an announcement.
On December 11, 2025, TransCode Therapeutics announced a collaboration with Quantum Leap Healthcare Collaborative to evaluate their lead therapeutic candidate, TTX-MC138, in a Phase 2a dose-expansion trial as part of the PRE-I-SPY clinical trial platform. The trial, set to begin in the first half of 2026, will enroll up to 45 colorectal cancer patients who are ctDNA positive after standard therapy. This collaboration aims to assess TTX-MC138’s efficacy in treating minimal residual disease, potentially offering a new therapeutic option for patients at risk of developing metastatic disease, following positive results from TransCode’s Phase 1 trial.
The most recent analyst rating on (RNAZ) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Underperform.
TransCode Therapeutics, as an early-stage biotech firm, presents a high-risk investment profile with significant financial challenges. The lack of revenue and increasing losses, coupled with negative equity, highlight financial instability. Technical indicators suggest continued downward pressure on the stock. The absence of a favorable valuation further impacts its attractiveness. Investors should be cautious given the speculative nature and financial health of the company.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
TransCode Therapeutics is a clinical stage company specializing in immunoncology and RNA therapeutic treatments for high-risk and advanced cancers. Their lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis, and they have a portfolio of other candidates aimed at mobilizing the immune system to combat cancer.
Average Trading Volume: 144,546
Technical Sentiment Signal: Sell
Current Market Cap: $7.71M
For detailed information about RNAZ stock, go to TipRanks’ Stock Analysis page.